Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Nash P, et al. Ann Rheum Dis. 2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6. Ann Rheum Dis. 2021. PMID: 33158881 Free PMC article.
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I; European Leflunomide Study Group. Scott DL, et al. Among authors: nash p. Ann Rheum Dis. 2001 Oct;60(10):913-23. doi: 10.1136/ard.60.10.913. Ann Rheum Dis. 2001. PMID: 11557646 Free PMC article. Clinical Trial.
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. van de Putte LB, et al. Among authors: nash p. Ann Rheum Dis. 2004 May;63(5):508-16. doi: 10.1136/ard.2003.013052. Ann Rheum Dis. 2004. PMID: 15082480 Free PMC article. Clinical Trial.
Seronegative spondyloarthropathies: to lump or split?
Nash P, Mease PJ, Braun J, van der Heijde D. Nash P, et al. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii9-13. doi: 10.1136/ard.2004.033654. Ann Rheum Dis. 2005. PMID: 15708947 Free PMC article. Review.
Outcome measures in psoriatic arthritis.
Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V. Gladman DD, et al. Among authors: nash p. J Rheumatol. 2007 May;34(5):1159-66. J Rheumatol. 2007. PMID: 17477479
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.
Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen JS, Khandker R, Singh A, Wajdula J, Fatenejad S; Etanercept European Investigators Network. Combe B, et al. Ann Rheum Dis. 2009 Jul;68(7):1146-52. doi: 10.1136/ard.2007.087106. Epub 2008 Sep 15. Ann Rheum Dis. 2009. PMID: 18794178 Free PMC article. Clinical Trial.
Treatment recommendations for psoriatic arthritis.
Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ritchlin CT, et al. Among authors: nash p. Ann Rheum Dis. 2009 Sep;68(9):1387-94. doi: 10.1136/ard.2008.094946. Epub 2008 Oct 24. Ann Rheum Dis. 2009. PMID: 18952643 Free PMC article. Review.
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Emery P, et al. Among authors: nash p. Arthritis Rheum. 2009 Aug;60(8):2272-83. doi: 10.1002/art.24638. Arthritis Rheum. 2009. PMID: 19644849 Free article. Clinical Trial.
560 results